Bausch Health
About: Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
Employees: 20,700
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
71% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 24
7% more funds holding
Funds holding: 208 [Q3] → 223 (+15) [Q4]
0.4% less ownership
Funds ownership: 69.27% [Q3] → 68.86% (-0.4%) [Q4]
4% less capital invested
Capital invested by funds: $2.08B [Q3] → $1.99B (-$86.1M) [Q4]
13% less funds holding in top 10
Funds holding in top 10: 8 [Q3] → 7 (-1) [Q4]
30% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 74
58% less call options, than puts
Call options by funds: $37.8M | Put options by funds: $89.1M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
54%
upside
Avg. target
$9
73%
upside
High target
$10
92%
upside
2 analyst ratings
0 positive
0%
2 neutral
100%
0 negative
0%
Jefferies David Steinberg 0 / 0 met price target | 54%upside $8 | Hold Downgraded | 6 Feb 2025 |
RBC Capital Douglas Miehm 42% 1-year accuracy 10 / 24 met price target | 92%upside $10 | Sector Perform Maintained | 30 Jan 2025 |
Financial journalist opinion
Based on 17 articles about BHC published over the past 30 days
Positive
WSJ
1 day ago
Bausch Health Learns Icahn Has 34% Economic Interest in Shares
Activist investor Carl Icahn has tightened his hold on pharmaceutical company Bausch Health.
Positive
Reuters
1 day ago
Bausch Health says Carl Icahn has exposure to about 34% of company's shares
Billionaire Carl Icahn has a total economic exposure of about 34% to Bausch Health's common shares, the healthcare firm said in a filing on Tuesday.
Neutral
Accesswire
1 day ago
Bausch Health Announces Filing of Supplement to Proxy Statement
Supplement In Response to Company Learning that Carl Icahn and Affiliates Have Cash-Settled Equity Swaps for Approximately 90 Million of Its Common Shares LAVAL, QC / ACCESS Newswire / April 22, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX: BHC) (the "Company" or "Bausch Health") today announced that it has filed a supplement (the "Proxy Statement Supplement") to its proxy statement dated April 2, 2025 (the "Proxy Statement") in respect of the Company's upcoming annual general meeting of shareholders on May 13, 2025. The Company is updating the Proxy Statement to disclose, in addition to the 34,721,118 common shares reported as being beneficially owned (9.4%), Mr.
Positive
Zacks Investment Research
2 days ago
Bausch (BHC) Moves 13.3% Higher: Will This Strength Last?
Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neutral
Business Wire
2 days ago
Bausch + Lomb Reports More Than 100 Million Units of Contacts Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE Recycling and Biotrue Eye Care Recycling programs have collected a total of 103,169,500 units, or 625,026 pounds, of used contact lenses, eye care and lens care materials in the United States. That's equivalent to the weight of approximately 600 concert grand pianos1. “These award-winnin.
Neutral
Accesswire
5 days ago
U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich
LAVAL, QC / ACCESS Newswire / April 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), and its gastroenterology business Salix Pharmaceuticals, Inc., today announced the U.S. District Court for the District of Columbia in the matter of Norwich Pharmaceuticals, Inc. v. Kennedy, et al.
Neutral
Accesswire
1 week ago
Bausch Health Announces Adoption of Shareholder Rights Plan
LAVAL, QC / ACCESS Newswire / April 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") announces today that its board of directors (the "Board") has approved the adoption of a shareholder rights plan (the "SRP") pursuant to a shareholder rights plan agreement entered into with TSX Trust Company, as rights agent, dated April 14, 2025 (the "Effective Date"). The SRP has been adopted to help ensure that all shareholders of the Company are treated fairly and equally in connection with any unsolicited take-over bid or other acquisition of control of the Company (including by way of a "creeping" take-over bid) and that the Board has the opportunity to identify, solicit, develop and negotiate value-enhancing alternatives to any unsolicited take-over bid or similar transaction.
Neutral
Accesswire
1 week ago
Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program
Bausch Health is offering scholarships to six students impacted by dermatologic conditions, with application submissions open through June 11, 2025 LAVAL, QC / ACCESS Newswire / April 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC)and its dermatology business, Ortho Dermatologics, today announced the 2025 ASPIRE HIGHER Scholarship Program is now open for application submissions through June 11, 2025. The program will award six exceptional students, impacted by dermatologic conditions, a scholarship of up to $10,000 in support of their higher education goals.
Neutral
Accesswire
2 weeks ago
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris
LAVAL, QC / ACCESS Newswire / April 9, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that it has signed a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA) for Canadian public drug plan coverage for PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% w/w, a new triple-combination topical prescription treatment for acne vulgaris in patients 12 years of age and older.1 The letter of intent means Bausch Health, Canada Inc. can now proceed to finalizing individual listing agreements for CABTREO to be covered by each of Canada's government drug plans, including those of all provinces and territories and the federal government (including plans for veterans and Indigenous peoples). The letter of intent spells out the agreed terms of those listing agreements, given the participation of all Canadian public drug plans in the pCPA process.
Positive
Seeking Alpha
2 weeks ago
Bausch Health: Repositioning Aplezin As First Oral Monotherapy For TRD A $3 Billion Opportunity
One-eighth of the global population and one-fifth of U.S. adults suffer from mental health conditions, highlighting an urgent need for better psychiatric care. Bausch Health's Aplenzin shows promise for treatment-resistant depression (TRD), potentially offering better efficacy and tolerability compared to Wellbutrin, addressing a significant unmet medical need. Repositioning Aplenzin for TRD could unlock a $3 billion market opportunity, aiding Bausch Health's financial recovery and providing substantial clinical benefits.
Charts implemented using Lightweight Charts™